1
|
Hong DZ, Ong TCC, Timbadia DP, Tan HTA, Kwa ED, Chong WQ, Goh BC, Loh WS, Loh KS, Tan EC, Tay JK. Systematic Review and Meta-Analysis of the Influence of Genetic Variation on Ototoxicity in Platinum-Based Chemotherapy. Otolaryngol Head Neck Surg 2023; 168:1324-1337. [PMID: 36802061 DOI: 10.1002/ohn.222] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2022] [Revised: 11/04/2022] [Accepted: 11/19/2022] [Indexed: 02/19/2023]
Abstract
OBJECTIVE The objective of this meta-analysis is to evaluate the impact of genetic polymorphisms on platinum-based chemotherapy (PBC)-induced ototoxicity. DATA SOURCES Systematic searches of PubMed, Embase, Cochrane, and Web of Science were conducted from the inception of the databases to May 31, 2022. Abstracts and presentations from conferences were also reviewed. REVIEW METHODS Four investigators independently extracted data in adherence to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Differences in the prevalence of PBC-induced ototoxicity between reference and variant (i) genotypes and (ii) alleles were analyzed. The overall effect size was presented using the random-effects model as an odds ratio (OR) with a 95% confidence interval (CI). RESULTS From 32 included articles, 59 single nucleotide polymorphisms on 28 genes were identified, with 4406 total unique participants. For allele frequency analysis, the A allele in ACYP2 rs1872328 was positively associated with ototoxicity (OR: 2.61; 95% CI: 1.06-6.43; n = 2518). Upon limiting to cisplatin use only, the T allele of COMT rs4646316 and COMT rs9332377 revealed significant results. For genotype frequency analysis, the CT/TT genotype in ERCC2 rs1799793 demonstrated an otoprotective effect (OR: 0.50; 95% CI: 0.27-0.94; n = 176). Excluding studies using carboplatin or concomitant radiotherapy revealed significant effects with COMT rs4646316, GSTP1 rs1965, and XPC rs2228001. Major sources of variations between studies include differences in patient demographics, ototoxicity grading systems, and treatment protocols. CONCLUSION Our meta-analysis presents polymorphisms that exert ototoxic or otoprotective effects in patients undergoing PBC. Importantly, several of these alleles are observed at high frequencies globally, highlighting the potential for polygenic screening and cumulative risk evaluation for personalized care.
Collapse
Affiliation(s)
- Daniel Z Hong
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
| | - Thaned C C Ong
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
| | - Dhayan P Timbadia
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
| | - Hui T A Tan
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
| | - Eunice D Kwa
- Department of Otolaryngology-Head and Neck Surgery, National University Hospital, Singapore, Singapore
| | - Wan Q Chong
- Department of Haematology-Oncology, National University Hospital, Singapore, Singapore
| | - Boon C Goh
- Department of Haematology-Oncology, National University Hospital, Singapore, Singapore
| | - Woei S Loh
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
- Department of Otolaryngology-Head and Neck Surgery, National University Hospital, Singapore, Singapore
| | - Kwok S Loh
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
- Department of Otolaryngology-Head and Neck Surgery, National University Hospital, Singapore, Singapore
| | - Ene C Tan
- KK Research Centre, KK Women's and Children's Hospital, Singapore, Singapore
| | - Joshua K Tay
- Department of Otolaryngology-Head and Neck Surgery, National University of Singapore, Singapore, Singapore
- Department of Otolaryngology-Head and Neck Surgery, National University Hospital, Singapore, Singapore
| |
Collapse
|
2
|
Núñez-Batalla F, Jáudenes-Casaubón C, Sequí-Canet JM, Vivanco-Allende A, Zubicaray-Ugarteche J. Ototoxicity in childhood: Recommendations of the CODEPEH (Commission for the Early Detection of Childhood Hearing Loss) for prevention and early diagnosis. ACTA OTORRINOLARINGOLOGICA ESPANOLA 2022; 73:255-265. [PMID: 35872300 DOI: 10.1016/j.otoeng.2022.07.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2021] [Accepted: 07/18/2021] [Indexed: 11/22/2022]
Abstract
Ototoxicity is defined as the damage, reversible or irreversible, produced in the inner ear by various substances that are called ototoxic and that can cause hearing loss and/or an alteration of the vestibular system. Permanent hearing loss significantly affects quality of life and is especially important in children. The lack or delay in its detection is frequent, since it often progresses in an inconspicuous manner until it affects communication and overall development. This impact can be minimized by following a strategy of audiological monitoring of ototoxicity, which allows for its early detection and treatment. This document recommends that children who are going to be treated with cisplatin or aminoglycosides be monitored. This CODEPEH review and recommendation document focuses on the early detection, prophylaxis, otoprotection, monitoring and treatment of ototoxicity caused by aminoglycosides and platinum-based antineoplastics in the paediatric population.
Collapse
|
3
|
Ototoxicidad en la edad pediátrica: recomendaciones de la CODEPEH (Comisión para la Detección Precoz de la Hipoacusia infantil) para su prevención y diagnóstico precoz. ACTA OTORRINOLARINGOLOGICA ESPANOLA 2022. [DOI: 10.1016/j.otorri.2021.07.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
4
|
Li P, Liu Z, Wang J, Bi X, Xiao Y, Qiao R, Zhou X, Guo S, Wan P, Chang M, Hong G, Liu Z, Ming X, Gao J, Fu X. Gstm1/Gstt1 is essential for reducing cisplatin ototoxicity in CBA/CaJ mice. FASEB J 2022; 36:e22373. [PMID: 35621716 DOI: 10.1096/fj.202200324r] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 04/30/2022] [Accepted: 05/12/2022] [Indexed: 11/11/2022]
Abstract
Cisplatin is a widely used chemotherapeutic agent. However, its clinical utility is limited because of cisplatin-induced ototoxicity. Glutathione S-transferase (GST) was found to play a vital role in reducing cisplatin ototoxicity in mice. Deletion polymorphisms of GSTM1 and GSTT1, members of the GST family, are common in humans and are presumed to be associated with cisplatin-induced hearing impairment. However, the specific roles of GSTM1 and GSTT1 in cisplatin ototoxicity are not completely clear. Here, under cisplatin treatment, simultaneous deletion of Gstm1 and Gstt1 lead to a more profound hearing loss in CBA/CaJ mice (Gstm1/Gstt1-DKO) than in wild-type mice. The Gstm1/Gstt1-DKO mice, in which phase II detoxification genes were upregulated, exhibited more severe oxidative stress and higher outer hair cell apoptosis in the cochleae than the control mice. Thus, our study revealed that Gstm1 and Gstt1 protect auditory hair cells from cisplatin-induced ototoxicity in the CBA/CaJ mice, and genetic screening for GSTM1 and GSTT1 polymorphisms could help determine a standard cisplatin dose for cancer patients undergoing chemotherapy.
Collapse
Affiliation(s)
- Peipei Li
- Department of Integrated Traditional and Western Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Province Research Center For Kidney Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Ziyi Liu
- Shandong Provincial Hospital, Shandong First Medical University, Jinan, China
| | - Jinpeng Wang
- The Key Laboratory of Animal Resistant Biology of Shandong Province, College of Life Science, Shandong Normal University, Jinan, China
| | - Xiuli Bi
- Shandong Provincial Hospital, Shandong First Medical University, Jinan, China
| | - Yu Xiao
- School of Life Science, Shandong University, Qingdao, China
| | - Ruifeng Qiao
- Shandong Provincial Hospital, Shandong First Medical University, Jinan, China
| | - Xuanchen Zhou
- Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Siwei Guo
- School of Life Science, Shandong University, Qingdao, China
| | - Peifeng Wan
- School of Life Science, Shandong University, Qingdao, China
| | - Miao Chang
- Shandong Provincial Hospital, Shandong First Medical University, Jinan, China
| | - Guodong Hong
- State Key Laboratory of Bioelectronics, Department of Otolaryngology Head and Neck Surgery, Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Jiangsu Province High-Tech Key Laboratory for Bio-Medical Research, Southeast University, Nanjing, China
| | - Zhangsuo Liu
- Department of Integrated Traditional and Western Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.,Henan Province Research Center For Kidney Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Xia Ming
- Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
| | - Jiangang Gao
- Shandong Provincial Hospital, Shandong First Medical University, Jinan, China
| | - Xiaolong Fu
- Shandong Provincial Hospital, Shandong First Medical University, Jinan, China.,Department of Otorhinolaryngology Head and Neck Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.,State Key Laboratory of Bioelectronics, Department of Otolaryngology Head and Neck Surgery, Zhongda Hospital, School of Life Sciences and Technology, Advanced Institute for Life and Health, Jiangsu Province High-Tech Key Laboratory for Bio-Medical Research, Southeast University, Nanjing, China
| |
Collapse
|
5
|
Sánchez-Canteli M, Núñez-Batalla F, Martínez-González P, de Lucio-Delgado A, Antonio Villegas-Rubio J, Gómez-Martínez JR, Luis Llorente-Pendás J. Ototoxicity in cancer survivors: Experience and proposal of a surveillance protocol. An Pediatr (Barc) 2021; 95:290-297. [PMID: 34702687 DOI: 10.1016/j.anpede.2020.08.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Accepted: 08/26/2020] [Indexed: 11/18/2022] Open
Abstract
INTRODUCTION Ototoxicity occurs in different percentages in patients after treatment with platinum-based chemotherapy or cranial radiation therapy. The aim of this study was to present our experience in ototoxicity monitoring. MATERIAL AND METHODS A review was made of the registry of paediatric cancer patients referred to the Children's Hearing Loss Unit from 1999 to 2019. RESULTS Of the 46 patients referred to this unit, 41 had received platinum as part of their treatment, 17 patients underwent neurosurgery, and 18 patients received cranial radiation therapy. An anamnesis and otoscopy were performed on all of them, and the monitoring was carried out with tone-verbal audiometry and/or distortion products. Hearing loss was observed in eight patients (21.05% of patients referred for audiological follow-up) as a consequence of the treatment. It was impossible to determine the audiological situation in eight patients at the end of treatment. Hearing aid adaption was necessary in two patients. In coordination with Paediatric Oncology, a change from cisplatin to carboplatin due to bilateral grade two ototoxicity was considered appropriate during treatment in one patient. CONCLUSION Adequate coordination with Paediatric Oncology is essential to carry out active surveillance for ototoxicity and to modify, if possible, the dosage or type of chemotherapy in case hearing is affected. In our experience, and following current recommendations, a pre-treatment assessment is usually performed, as well as monitoring during treatment, at the end of treatment, and annually thereafter due to the risk of a later development of hearing loss.
Collapse
Affiliation(s)
- Mario Sánchez-Canteli
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain.
| | - Faustino Núñez-Batalla
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain
| | - Patricia Martínez-González
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, Spain
| | - Ana de Lucio-Delgado
- Oncología Pediátrica, Servicio de Pediatría, Hospital Universitario Central de Asturias, Oviedo, Spain
| | | | - Justo Ramón Gómez-Martínez
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain
| | - José Luis Llorente-Pendás
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, Spain; Universidad de Oviedo, Oviedo, Spain
| |
Collapse
|
6
|
Sánchez-Canteli M, Núñez-Batalla F, Martínez-González P, de Lucio-Delgado A, Villegas-Rubio JA, Gómez-Martínez JR, Llorente-Pendás JL. [Ototoxicity in cancer survivors: experience and proposal of a surveillance protocol]. An Pediatr (Barc) 2020; 95:S1695-4033(20)30296-4. [PMID: 32998843 DOI: 10.1016/j.anpedi.2020.08.008] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 08/25/2020] [Accepted: 08/26/2020] [Indexed: 01/18/2023] Open
Abstract
INTRODUCTION Ototoxicity occurs in different percentages in patients after treatment with platinum-based chemotherapy or cranial radiation therapy. The aim of this study was to present experience in ototoxicity monitoring. MATERIAL AND METHODS A review was made of the registry of paediatric cancer patients referred to the Children's Hearing Loss Unit from 1999 to 2019. RESULTS Of the 46 patients referred to this unit, 41 had received platinum as part of their treatment, 17 patients underwent neurosurgery, and 18 patients received cranial radiation therapy. An anamnesis and otoscopy were performed on all of them, and the monitoring was carried out with tone-verbal audiometry and/or distortion products. Hearing loss was observed in eight patients (21.05% of patients referred for audiological follow-up) as a consequence of the treatment. It was impossible to determine the audiological situation in eight patients at the end of treatment. Hearing aid adaption was necessary in two patients. In coordination with Paediatric Oncology, a change from cisplatin to carboplatin due to bilateral grade two ototoxicity was considered appropriate during treatment in one patient. CONCLUSION Adequate coordination with Paediatric Oncology is essential to carry out active surveillance for ototoxicity and to modify, if possible, the dosage or type of chemotherapy in case hearing is affected. In our experience, and following current recommendations, a pre-treatment assessment is usually performed, as well as monitoring during treatment, at the end of treatment, and annually thereafter due to the risk of a later development of hearing loss.
Collapse
Affiliation(s)
- Mario Sánchez-Canteli
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, España; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, España.
| | - Faustino Núñez-Batalla
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, España; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, España; Universidad de Oviedo, Oviedo, España
| | - Patricia Martínez-González
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, España
| | - Ana de Lucio-Delgado
- Oncología Pediátrica, Servicio de Pediatría, Hospital Universitario Central de Asturias, Oviedo, España
| | | | - Justo Ramón Gómez-Martínez
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, España; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, España; Universidad de Oviedo, Oviedo, España
| | - José Luis Llorente-Pendás
- Unidad de Hipoacusia Infantil, Servicio de Otorrinolaringología, Hospital Universitario Central de Asturias, Oviedo, España; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA), Oviedo, España; Universidad de Oviedo, Oviedo, España
| |
Collapse
|
7
|
GSTM1 null and GSTT1 null: predictors of cisplatin-caused acute ototoxicity measured by DPOAEs. J Mol Med (Berl) 2020; 98:963-971. [PMID: 32435918 PMCID: PMC7343745 DOI: 10.1007/s00109-020-01921-y] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 05/05/2020] [Accepted: 05/07/2020] [Indexed: 01/08/2023]
Abstract
Preventing the ototoxicity caused by cisplatin is a major issue yet to be overcome. Useful preventive treatments will soon be available. Consequently, the next step is to filter out those patients who are more prone to develop ototoxicity. The aim of this study was to prospectively evaluate potential predictive markers of acute ototoxicity as determined by measures of distortion product otoacoustic emissions (DPOAEs). A total of 118 patients from our previous DPOAE analysis were put under evaluation. Ototoxic cases were divided according to unilateral (n = 45) or bilateral (n = 23) involvement. The clinicopathological characteristics, hearing test results, germline GSTT1, GSTM1, and GSTP1 polymorphisms, and common laboratory parameters were included in the new analysis. Univariate and multivariate statistical tests were applied. According to multivariate logistic regression, the only independent predictor of unilateral ototoxicity (vs. non-affected) was a GSTM1 null genotype (OR = 4.52; 95%CI = 1.3-16.3), while for bilateral damage, the GSTT1 null genotype (OR = 4.76; 1.4-16) was a predictor. The higher starting serum urea level was characteristic of bilateral ototoxicity; however, the only independent marker of bilateral (vs. unilateral) ototoxicity was the presence of GSTT1 null genotype (OR = 2.44; 1.23-4.85). Different processes, involving the GSTM1 and GSTT1 genotypes, respectively, govern the development of acute unilateral and bilateral ototoxicities. Further research is needed to clarify these processes. Based on the above findings, patients whom are at risk may be selected for otoprotective therapies. KEY MESSAGES: The acute ototoxicity was determined by DPOAE in 118 testicular cancer patients. GSTM1 null was the only marker of unilateral ototoxicity (vs. non-affected). The only marker of bilateral hearing loss (vs. non-affected) was the GSTT1 null. GSTT1 null was also the marker of bilateral vs. unilateral ototoxicity. A high-risk group may be selected for new, individualized otoprotective treatment.
Collapse
|
8
|
Clemens E, van den Heuvel-Eibrink MM, Mulder RL, Kremer LCM, Hudson MM, Skinner R, Constine LS, Bass JK, Kuehni CE, Langer T, van Dalen EC, Bardi E, Bonne NX, Brock PR, Brooks B, Carleton B, Caron E, Chang KW, Johnston K, Knight K, Nathan PC, Orgel E, Prasad PK, Rottenberg J, Scheinemann K, de Vries ACH, Walwyn T, Weiss A, Am Zehnhoff-Dinnesen A, Cohn RJ, Landier W. Recommendations for ototoxicity surveillance for childhood, adolescent, and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group in collaboration with the PanCare Consortium. Lancet Oncol 2019; 20:e29-e41. [PMID: 30614474 PMCID: PMC7549756 DOI: 10.1016/s1470-2045(18)30858-1] [Citation(s) in RCA: 73] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2018] [Revised: 11/06/2018] [Accepted: 11/07/2018] [Indexed: 01/26/2023]
Abstract
Childhood, adolescent, and young adult (CAYA) cancer survivors treated with platinum-based drugs, head or brain radiotherapy, or both have an increased risk of ototoxicity (hearing loss, tinnitus, or both). To ensure optimal care and reduce consequent problems-such as speech and language, social-emotional development, and learning difficulties-for these CAYA cancer survivors, clinical practice guidelines for monitoring ototoxicity are essential. The implementation of surveillance across clinical settings is hindered by differences in definitions of hearing loss, recommendations for surveillance modalities, and remediation. To address these deficiencies, the International Guideline Harmonization Group organised an international multidisciplinary panel, including 32 experts from ten countries, to evaluate the quality of evidence for ototoxicity following platinum-based chemotherapy and head or brain radiotherapy, and formulate and harmonise ototoxicity surveillance recommendations for CAYA cancer survivors.
Collapse
Affiliation(s)
- Eva Clemens
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
| | | | - Renée L Mulder
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Leontien C M Kremer
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Melissa M Hudson
- Department of Oncology, St Jude Children's Research Hospital, Memphis, TN, USA; Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Roderick Skinner
- Department of Pediatric and Adolescent Hematology/Oncology and Children's Hematopoietic Stem Cell Transplant Unit, Great North Children's Hospital and Institute of Cancer Research, Newcastle University, Newcastle upon Tyne, UK
| | - Louis S Constine
- Departments of Radiation Oncology and Pediatrics, University of Rochester Medical Center, Rochester, New York, NY, USA
| | - Johnnie K Bass
- Rehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Claudia E Kuehni
- Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Department of Pediatrics, Children's University Hospital of Bern, University of Bern, Bern, Switzerland
| | - Thorsten Langer
- Pediatric Oncology and Hematology, University Hospital for Children and Adolescents, Lübeck, Germany
| | - Elvira C van Dalen
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, University of Amsterdam, Amsterdam, Netherlands
| | - Edith Bardi
- Department of Pediatrics and Adolescent Medicine, Kepler Universitätsklinikum, Linz, Austria
| | | | - Penelope R Brock
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Beth Brooks
- Rehabilitation Services, St Jude Children's Research Hospital, Memphis, TN, USA; Audiology and Speech Pathology Department, British Columbia's Children's Hospital, Vancouver, BC, Canada; School of Audiology and Speech Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Bruce Carleton
- Pharmaceutical Outcomes Programme, British Columbia's Children's Hospital, Vancouver, BC, Canada; Department of Pediatrics, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada
| | - Eric Caron
- Department of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, TN, USA
| | - Kay W Chang
- Department of Otolaryngology, Stanford University, Palo Alto, CA, USA
| | - Karen Johnston
- Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia
| | - Kristin Knight
- Department of Pediatric Audiology, Child Development and Rehabilitation Center, Doernbecher Children's Hospital, Oregon Health and Science University, Portland, OR, USA
| | - Paul C Nathan
- Department of Pediatrics, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada
| | - Etan Orgel
- Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles, Los Angeles, CA, USA; Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
| | - Pinki K Prasad
- Department of Pediatrics, Louisiana State University Health Sciences Center, New Orleans, LA, USA; Division of Pediatric Hematology/Oncology, Children's Hospital of New Orleans, New Orleans, LA, USA
| | - Jan Rottenberg
- Department of Otolaryngology and Head and Neck Surgery, St Ann's University Hospital Brno, Masaryk University, Brno, Czech Republic
| | - Katrin Scheinemann
- Division of Pediatric Hematology/Oncology, Hospital for Children and Adolescents, Cantonal Hospital Aarau, Aarau, Switzerland; Division of Pediatric Hematology/Oncology, University for Children's Hospital Basel, Basel, Switzerland; Division of Pediatric Hematology/Oncology, McMaster Children's Hospital, McMaster University, Hamilton, ON, Canada
| | - Andrica C H de Vries
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands; Department of Pediatric Hematology and Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, Netherlands
| | - Thomas Walwyn
- Department of Pediatric and Adolescent Oncology, Perth Children's Hospital, Nedlands, WA, Australia; School of Medicine, University of Western Australia, Perth, WA, Australia
| | - Annette Weiss
- Swiss Childhood Cancer Registry, Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland; Institute of Epidemiology and Preventive Medicine, University of Regensburg, Regensburg, Germany
| | - Antoinette Am Zehnhoff-Dinnesen
- Department of Phoniatrics and Pedaudiology, University Hospital Münster, Westphalian Wilhelm University of Münster, Münster, Germany
| | - Richard J Cohn
- Kids Cancer Centre, Sydney Children's Hospital, High Street, Randwick, NSW, Australia; School of Women's and Children's Health, University of New South Wales Medicine, Sydney, NSW, Australia
| | - Wendy Landier
- Institute for Cancer Outcomes and Survivorship, Department of Pediatrics, School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, AL, USA.
| |
Collapse
|
9
|
Global burden of hearing impairment and ear disease. The Journal of Laryngology & Otology 2018; 133:18-25. [DOI: 10.1017/s0022215118001275] [Citation(s) in RCA: 75] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
AbstractBackgroundHearing loss can present at birth or be acquired as a result of illness, middle-ear disease, injury, age, overuse of certain medications, and/or induced by exposure to damaging noise levels. There are serious short-term consequences for people living with hearing impairment, including the effects on language acquisition, education, employment and overall wellbeing. There are also complex long-term implications.ObjectivesThis review aimed to present some of the leading causes of ear disease and hearing loss globally, and to identify their impact at both an individual and societal level.
Collapse
|
10
|
Lanvers-Kaminsky C, Zehnhoff-Dinnesen AA, Parfitt R, Ciarimboli G. Drug-induced ototoxicity: Mechanisms, Pharmacogenetics, and protective strategies. Clin Pharmacol Ther 2017; 101:491-500. [PMID: 28002638 DOI: 10.1002/cpt.603] [Citation(s) in RCA: 157] [Impact Index Per Article: 22.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2016] [Revised: 11/21/2016] [Accepted: 12/08/2016] [Indexed: 01/08/2023]
Abstract
Drug ototoxicity limits the quality of life of patients after treatment, having serious consequences, especially for psychosocial development of children. Although the ototoxicity of many drugs resolves after treatment discontinuation, the use of platinum derivatives and aminoglycosides is associated with permanent hearing loss. In this review, we have listed ototoxic drugs and the mechanisms by which they damage the ears. Moreover, possible protective strategies and important methods for early detection of ototoxic effects are discussed.
Collapse
Affiliation(s)
- C Lanvers-Kaminsky
- Department of Pediatric Hematology and Oncology, University Children's Hospital of Muenster, Muenster, Germany
| | - Ag Am Zehnhoff-Dinnesen
- Department of Phoniatrics and Pedaudiology, University Hospital of Muenster, Muenster, Germany
| | - R Parfitt
- Department of Phoniatrics and Pedaudiology, University Hospital of Muenster, Muenster, Germany
| | - G Ciarimboli
- Experimental Nephrology, Department of Internal Medicine D, University Hospital of Muenster, Muenster, Germany
| |
Collapse
|
11
|
Knight KR, Chen L, Freyer D, Aplenc R, Bancroft M, Bliss B, Dang H, Gillmeister B, Hendershot E, Kraemer DF, Lindenfeld L, Meza J, Neuwelt EA, Pollock BH, Sung L. Group-Wide, Prospective Study of Ototoxicity Assessment in Children Receiving Cisplatin Chemotherapy (ACCL05C1): A Report From the Children's Oncology Group. J Clin Oncol 2017; 35:440-445. [PMID: 27937095 PMCID: PMC5455699 DOI: 10.1200/jco.2016.69.2319] [Citation(s) in RCA: 57] [Impact Index Per Article: 8.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022] Open
Abstract
Purpose Optimal assessment methods and criteria for reporting hearing outcomes in children who receive treatment with cisplatin are uncertain. The objectives of our study were to compare different ototoxicity classification systems, to evaluate the feasibility of including otoacoustic emissions and extended high frequency audiometry, and to evaluate a central review mechanism for audiologic results for cisplatin-treated children in the cooperative group setting. Patients and Methods Eligible participants were 1 to 30 years, with planned cisplatin-containing treatment. Hearing evaluations were conducted at baseline, before each cisplatin cycle, and at the end of therapy. Audiologic results were assessed and graded by the testing audiologist and by two central review audiologists using the American Speech-Language-Hearing Association Ototoxicity Criteria (ASHA), Common Terminology Criteria for Adverse Events, version 3.0 (CTCAE), and Brock Ototoxicity Grades (Brock). One central reviewer also used the International Society of Pediatric Oncology Ototoxicity Scale (SIOP). Results At the end of treatment, the prevalence of any degree of ototoxicity ranged from 40% to 56%, and severe ototoxicity ranged from 7% to 22%. Compared with CTCAE, SIOP detected significantly more ototoxicity ( P = .004), whereas Brock criteria detected significantly fewer patients with any or severe ototoxicity ( P < .001 for both). SIOP detected ototoxicity earlier than did the other scales. Agreement between the central reviewers and the institutional audiologist was almost perfect for ASHA and Brock, whereas the poorest agreement occurred with CTCAE. Conclusion The SIOP scale may be superior to ASHA, Brock, and CTCAE scales for classifying ototoxicity in pediatric patients who were treated with cisplatin. Future studies should evaluate inter-rater reliability of the SIOP scale.
Collapse
Affiliation(s)
- Kristin R. Knight
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Lu Chen
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - David Freyer
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Richard Aplenc
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Mary Bancroft
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Bonnie Bliss
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Ha Dang
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Biljana Gillmeister
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Eleanor Hendershot
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Dale F. Kraemer
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Lanie Lindenfeld
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Jane Meza
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Edward A. Neuwelt
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Brad H. Pollock
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| | - Lillian Sung
- Kristin R. Knight and Edward A. Neuwelt, Oregon Health and Science University, Portland, OR; Lu Chen and Ha Dang, Children’s Oncology Group, Monrovia; David Freyer, Children’s Hospital Los Angeles; Ha Dang, University of Southern California, Los Angeles; Lanie Lindenfeld, City of Hope, Duarte; Brad H. Pollock, University of California, Davis, Davis, CA; Richard Aplenc, Children’s Hospital of Philadelphia, Philadelphia, PA; Mary Bancroft, University of Florida, Gainesville; Dale F. Kraemer, University of Florida, Jacksonville, FL; Bonnie Bliss, Biljana Gillmeister, Jane Meza, and Lillian Sung, The Hospital for Sick Children, Toronto; and Eleanor Hendershot, McMaster Children’s Hospital, Hamilton, Ontario, Canada
| |
Collapse
|
12
|
Mendes SRO, Amado AM, Tomkinson J, Marques MPM, Batista de Carvalho LAE. Vibrational and conformational studies of 1,3-diaminopropane and its N-deuterated and N-ionised derivatives. NEW J CHEM 2017. [DOI: 10.1039/c7nj00810d] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A scarce understanding of the biological role of 1,3-diaminopropane highlights the relevance of attaining its full conformational preferences, using combined FTIR, Raman and INS spectroscopies.
Collapse
Affiliation(s)
- Sofia R. O. Mendes
- Unidade de I&D “Química-Física Molecular”
- Department of Chemistry
- University of Coimbra
- 3004-535 Coimbra
- Portugal
| | - Ana M. Amado
- Unidade de I&D “Química-Física Molecular”
- Department of Chemistry
- University of Coimbra
- 3004-535 Coimbra
- Portugal
| | - John Tomkinson
- ISIS Facility
- STFC Rutherford Appleton Laboratory
- Didcot
- UK
| | - M. Paula M. Marques
- Unidade de I&D “Química-Física Molecular”
- Department of Chemistry
- University of Coimbra
- 3004-535 Coimbra
- Portugal
| | | |
Collapse
|
13
|
Noszek L, Budai B, Prekopp P, Széchenyi R, Szőnyi M, Talpai S, Nagyiványi K, Bíró K, Géczi L. Early ototoxic changes in patients with germ cell tumor after first cycle of cisplatin-based therapy. Laryngoscope 2016; 127:E277-E282. [DOI: 10.1002/lary.26325] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/16/2016] [Indexed: 12/25/2022]
Affiliation(s)
- László Noszek
- Department of Otorhinolaryngology, Head and Neck Surgery; Semmelweis University; Budapest Hungary
| | - Barna Budai
- Department of Molecular Immunology and Toxicology; National Institute of Oncology; Budapest Hungary
| | - Péter Prekopp
- Department of Otorhinolaryngology, Head and Neck Surgery; Semmelweis University; Budapest Hungary
| | | | - Márta Szőnyi
- Department of Oncology; Szent Margit Hospital; Budapest Hungary
| | - Szabolcs Talpai
- Department of Otorhinolaryngology, Head and Neck Surgery; Semmelweis University; Budapest Hungary
| | - Krisztián Nagyiványi
- Department of Medical Oncology and Clinical Pharmacology “C”; National Institute of Oncology; Budapest Hungary
| | - Krisztina Bíró
- Department of Medical Oncology and Clinical Pharmacology “C”; National Institute of Oncology; Budapest Hungary
| | - Lajos Géczi
- Department of Medical Oncology and Clinical Pharmacology “C”; National Institute of Oncology; Budapest Hungary
| |
Collapse
|
14
|
Dille MF, Wilmington D, McMillan GP, Helt W, Fausti SA, Konrad-Martin D. Development and validation of a cisplatin dose-ototoxicity model. J Am Acad Audiol 2012; 23:510-21. [PMID: 22992258 PMCID: PMC5549622 DOI: 10.3766/jaaa.23.7.3] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
BACKGROUND Cisplatin is effective in the treatment of several cancers but is a known ototoxin resulting in shifts to hearing sensitivity in up to 50-60% of patients. Cisplatin-induced hearing shifts tend to occur first within an octave of a patient's high frequency hearing limit, termed the sensitive range for ototoxicity (SRO), and progress to lower frequencies. While it is currently not possible to know which patients will experience ototoxicity without testing their hearing directly, monitoring the SRO provides an early indication of damage. A tool to help forecast susceptibility to ototoxic-induced changes in the SRO in advance of each chemotherapy treatment visit may prove useful for ototoxicity monitoring efforts, patient counseling, and therapeutic planning. PURPOSE This project was designed to (1) establish pretreatment risk curves that quantify the probability that a new patient will suffer hearing loss within the SRO during treatment with cisplatin and (2) evaluate the accuracy of these predictions in an independent sample of Veterans receiving cisplatin for the treatment of cancer. STUDY SAMPLE Two study samples were used. The Developmental sample contained 23 subjects while the Validation sample consisted of 12 subjects. DATA COLLECTION AND ANALYSIS Risk curve predictions for SRO threshold shifts following cisplatin exposure were developed using a Developmental sample comprised of data from a total of 155 treatment visits obtained in 45 ears of 23 Veterans. Pure-tone thresholds were obtained within each subject's SRO at each treatment visit and compared with baseline measures. The risk of incurring an SRO shift was statistically modeled as a function of factors related to chemotherapy treatment (cisplatin dose, radiation treatment, doublet medication) and patient status (age, pre-exposure hearing, cancer location and stage). The model was reduced so that only statistically significant variables were included. Receiver-operating characteristic (ROC) curve analyses were then used to determine the accuracy of the risk curve predictions in an independent Validation sample of observations from over 62 treatment visits obtained in 24 ears of 12 Veterans. RESULTS Only cumulative cisplatin dose and pre-exposure hearing were found to be significantly related to the risk for hearing shift. The dose-ototoxicity risk curve predictions developed from the Developmental sample yielded area under the ROC curve accuracy estimates of 0.85 when applied to an independent Validation sample. CONCLUSIONS Cumulative cisplatin dose in combination with pre-exposure hearing provides an indication of whether hearing will shift in the SRO in advance of cisplatin administration. The validated dose-ototoxicity risk curves described herein can be used before and during treatment to anticipate hearing loss. While having such a tool would not replace serial hearing testing, it would be of great benefit to an ototoxicity monitoring program. It would promote relevant pretreatment counseling. Furthermore, for those found to be at risk of SRO shifts within the speech frequencies, the oncology treatment plan could incorporate anticipated dosing adjustments that could stave off the impact that ototoxicity might bring.
Collapse
Affiliation(s)
- Marilyn F Dille
- VA RR&D National Center for Rehabilitative Auditory Research, Veterans Affairs Medical Center, Portland, OR 97239, USA.
| | | | | | | | | | | |
Collapse
|
15
|
Zhang J. Auditory cortex stimulation to suppress tinnitus: mechanisms and strategies. Hear Res 2012; 295:38-57. [PMID: 22683861 DOI: 10.1016/j.heares.2012.05.007] [Citation(s) in RCA: 38] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/04/2012] [Revised: 05/06/2012] [Accepted: 05/14/2012] [Indexed: 01/08/2023]
Abstract
Brain stimulation is an important method used to modulate neural activity and suppress tinnitus. Several auditory and non-auditory brain regions have been targeted for stimulation. This paper reviews recent progress on auditory cortex (AC) stimulation to suppress tinnitus and its underlying neural mechanisms and stimulation strategies. At the same time, the author provides his opinions and hypotheses on both animal and human models. The author also proposes a medial geniculate body (MGB)-thalamic reticular nucleus (TRN)-Gating mechanism to reflect tinnitus-related neural information coming from upstream and downstream projection structures. The upstream structures include the lower auditory brainstem and midbrain structures. The downstream structures include the AC and certain limbic centers. Both upstream and downstream information is involved in a dynamic gating mechanism in the MGB together with the TRN. When abnormal gating occurs at the thalamic level, the spilled-out information interacts with the AC to generate tinnitus. The tinnitus signals at the MGB-TRN-Gating may be modulated by different forms of stimulations including brain stimulation. Each stimulation acts as a gain modulator to control the level of tinnitus signals at the MGB-TRN-Gate. This hypothesis may explain why different types of stimulation can induce tinnitus suppression. Depending on the tinnitus etiology, MGB-TRN-Gating may be different in levels and dynamics, which cause variability in tinnitus suppression induced by different gain controllers. This may explain why the induced suppression of tinnitus by one type of stimulation varies across individual patients.
Collapse
Affiliation(s)
- Jinsheng Zhang
- Department of Otolaryngology - Head and Neck Surgery, Wayne State University, School of Medicine, 5E-UHC, 4201 Saint Antoine, Detroit, MI 48201, USA.
| |
Collapse
|
16
|
Weissenstein A, Deuster D, Knief A, Zehnhoff-Dinnesen AA, Schmidt CM. Progressive hearing loss after completion of cisplatin chemotherapy is common and more pronounced in children without spontaneous otoacoustic emissions before chemotherapy. Int J Pediatr Otorhinolaryngol 2012; 76:131-6. [PMID: 22104469 DOI: 10.1016/j.ijporl.2011.10.020] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2011] [Revised: 10/20/2011] [Accepted: 10/22/2011] [Indexed: 11/16/2022]
Abstract
OBJECTIVE High frequency hearing loss following cisplatin chemotherapy is frequent in children and often necessitates the fitting of hearing aids. During therapy, hearing is usually monitored. Post-therapeutic follow-up does not routinely include monitoring of hearing, although there are indications that hearing thresholds can decline after therapy. METHODS Pure-tone audiograms taken from 27 children (17 males, 10 females) treated with cisplatin at Muenster university hospital (mean age 9.84 years, standard deviation 3.67 years) including an audiological follow-up at least 6 months after therapy, were analyzed retrospectively. RESULTS In follow-up tests after completion of therapy, 24.1% of all ears showed an increase in mean high frequency hearing thresholds (4-8 kHz). Post-therapeutic hearing deterioration was significant at 4 kHz and significantly more pronounced in children without measurable spontaneous otoacoustic emissions (SOAE) before therapy. Post-therapeutic hearing deterioration did not occur in ears with normal pure tone thresholds (≤ 10dB at all frequencies) after cisplatin therapy. No correlation was found between post-therapeutic hearing deterioration and cranial irradiation. CONCLUSIONS Cisplatin chemotherapy follow-up should include audiological monitoring in all children with elevated pure tone thresholds after therapy. Routine SOAE measurements taken as part of baseline audiometry before the start of chemotherapy can be taken into consideration.
Collapse
Affiliation(s)
- Anne Weissenstein
- Department of Phoniatrics and Pedaudiology, Muenster University Hospital, Kardinal-von-Galen-Ring 10, 48129 Muenster, Germany.
| | | | | | | | | |
Collapse
|
17
|
Noreña AJ. An integrative model of tinnitus based on a central gain controlling neural sensitivity. Neurosci Biobehav Rev 2011; 35:1089-109. [PMID: 21094182 DOI: 10.1016/j.neubiorev.2010.11.003] [Citation(s) in RCA: 285] [Impact Index Per Article: 21.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2010] [Revised: 10/20/2010] [Accepted: 11/12/2010] [Indexed: 02/03/2023]
|
18
|
|
19
|
Gao SS, Choi BM, Chen XY, Zhu RZ, Kim Y, So H, Park R, Sung M, Kim BR. Kaempferol suppresses cisplatin-induced apoptosis via inductions of heme oxygenase-1 and glutamate-cysteine ligase catalytic subunit in HEI-OC1 cell. Pharm Res 2010; 27:235-45. [PMID: 19937094 DOI: 10.1007/s11095-009-0003-3] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/03/2009] [Accepted: 10/26/2009] [Indexed: 01/22/2023]
Abstract
PURPOSE The present study was undertaken to elucidate the chemoprotective mechanism of kaempferol, which possesses anti-oxidative and anti-apoptotic properties. METHODS House Ear Institute-Organ of Corti 1 (HEI-OC1) cells were treated with kaempferol in the presence or absence of cisplatin. Cisplatin-induced oxidative stress was assessed by analysis of Comet assay, DNA-laddering assay and activation of caspases. Heme oxygenase-1 (HO-1), mitogen-activated protein kinase (MAPK) pathway and nuclear factor-E2-related factor 2 (Nrf2) were measured by Western blot analysis. Transfection of small interfering RNAs (siRNA), glutathione (GSH) assay and RT-PCR were performed in this study. RESULTS Kaempferol protected cells against cisplatin-induced apoptosis in a dose-dependent manner in HEI-OC1 cells. Kaempferol-induced HO-1 expression protected against cell death though the c-Jun N-terminal kinase (JNK) pathway and by the aid of Nrf2 translocation. Kaempferol increased the cellular level of GSH and the expression of GCLC time-dependently. siRNA GCLC blocked the increase of GSH level by kaempferol and the protective effect of kaempferol against cisplatin-induced cell death. CONCLUSION The expression of HO-1 by kaempferol inhibits cisplatin-induced apoptosis in HEI-OC1 cells, and the mechanism of protective effect is also associated with its inductive effect of GCLC expression.
Collapse
Affiliation(s)
- Shang Shang Gao
- Vestibulocochlear Research Center and Department of Biochemistry, School of Medicine, Wonkwang University, Chonbuk, 570-749, Republic of Korea
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Current awareness: Pharmacoepidemiology and drug safety. Pharmacoepidemiol Drug Saf 2008. [DOI: 10.1002/pds.1486] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|